医学
结缔组织病
内科学
结缔组织
狼疮性肾炎
临床意义
肾炎
胃肠病学
CTD公司
血管紧张素转化酶2
血清浓度
内分泌学
混合性结缔组织病
疾病
自身免疫性疾病
病理
2019年冠状病毒病(COVID-19)
传染病(医学专业)
地质学
海洋学
作者
Xiaojun Tang,Linyu Geng,Xuebing Feng,Lingyun Sun
出处
期刊:Rheumatology
[Oxford University Press]
日期:2020-12-28
卷期号:60 (9): 4401-4406
被引量:8
标识
DOI:10.1093/rheumatology/keaa898
摘要
Abstract Objective To evaluate serum concentration and activity of angiotensin-converting enzyme 2 (ACE2) in patients with connective tissue diseases (CTDs). Methods Serum samples from healthy subjects and patients with SLE, systemic sclerosis (SSc), primary Sjögren’s syndrome (SS) and RA were collected. The concentration and activity of ACE2 were measured by ELISA and fluorometric method, respectively, and analysed for associations with clinical features and concurrent medications. Results In total, 66 SLE, 55 SSc, 31 SS and 31 RA patients were involved. ACE2 concentration was significantly decreased in patients with either of the four CTDs compared with healthy subjects. The concentration was not linked to special clinical features expect that it was slightly lower in patients with lupus nephritis than those without. In SLE patients, ACE2 concentration elevated with the increase of glucocorticoids, and was not associated with other treatments. Different from the concentration, ACE2 activity was increased in CTD patients. A weak correlation of ACE2 activity with SLE disease activity index score was also observed. Conclusion The clinical significance of ACE2 concentration and activity looks quite different among CTD patients. Preliminary data suggest ACE2 levels are not affected by most of the treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI